Yi-Long Wu

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

China

Guangdong Academy of Medical Sciences, Guangdong General Hospital, Guangdong Lung Cancer Institute, Department of Pulmonary Oncology

China

SCHOLARLY PAPERS

6

DOWNLOADS

158

SSRN CITATIONS

3

CROSSREF CITATIONS

0

Scholarly Papers (6)

1.

Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 078 Randomised Phase 3 Clinical Trial

Number of pages: 31 Posted: 25 Sep 2018
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Shanghai Jiao Tong University (SJTU), Jilin Cancer Hospital, Tongji University - Department of Medical Oncology, Chinese Academy of Sciences (CAS), The Chinese University of Hong Kong (CUHK), Sun Yat-Sen University (SYSU), Guangdong Academy of Medical Sciences, Central South University - Hunan Cancer Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Zhejiang Cancer Hospital, Leningrad Regional Clinical Hospital, Zhejiang University, Zhengzhou University - Henan Cancer Hospital, Sichuan University - West China Hospital, Central South University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Bristol-Myers Squibb, Bristol-Myers Squibb and Fudan University
Downloads 54 (416,022)
Citation 3

Abstract:

Loading...

nivolumab; PD-1 inhibitor; non-small-cell lung cancer; NSCLC; China; docetaxel; immunotherapy

2.

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

Number of pages: 37 Posted: 28 Jan 2019
Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences
Downloads 28 (528,978)

Abstract:

Loading...

Abivertinib, resistance, EGFR amplification

3.

A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Number of pages: 40 Posted: 20 Jan 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Beijing Cancer Hospital, Nanjing Medical University - Department of Oncology, Fudan University, Harbin Medical University - Cancer Hospital, Guangzhou Medical University - First Affiliated Hospital, Jilin University (JLU) - First Affiliated Hospital, Government of the People's Republic of China - 307th Hospital, Central South University - Hunan Cancer Hospital, Tongji University - Shanghai Pulmonary Hospital, Soochow University - First Affiliated Hospital, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - China and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 23 (559,028)

Abstract:

Loading...

Savolitinib; Gefitinib; EGFR-TKI; NSCLC; China; MET

4.

Development and Validation of a Gene Mutation-Based Signature to Predict Response to PD-1 Inhibitors in Non-Squamous NSCLC: A Retrospective Multicohort Study

Number of pages: 38 Posted: 12 May 2019
Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Hepatology Unit, Saint Louis University - College for Public Health and Social Justice, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Department of Radiation Oncology, Southern Medical University - Hepatology Unit, Southern Medical University - Department of Radiation Oncology, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Southern Medical University - Department of Radiation Oncology
Downloads 22 (565,414)

Abstract:

Loading...

gene mutation-based signature (GMS); non-squamous non-small cell lung cancer; PD-1/PD-L1; predictive; immunotherapy

5.

Wait-and-See Treatment Strategy and Genomic Alternations Associated with Progression in Lung Adenocarcinoma with Pleural Dissemination

Number of pages: 28 Posted: 09 May 2019
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangzhou University of Chinese Medicine, Geneseeq Technology Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc., Geneseeq Technology Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Geneseeq Technology Inc. - Nanjing Geneseeq Technology Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 18 (591,521)

Abstract:

Loading...

Lung adenocarcinoma, pleural dissemination, wait-and-see, genome instability, progression

6.

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Number of pages: 29 Posted: 06 Dec 2018
Government of the People's Republic of China - 307th Hospital, Government of the People's Republic of China - 307th Hospital, Chinese Academy of Medical Sciences, Zhejiang University, Chinese Academy of Medical Sciences, Central South University, Peking University - Cancer Hospital and Institute, Jilin Province Cancer Hospital, Chinese Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, ACEA Pharmaceutical Research, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc. and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 13 (625,340)

Abstract:

Loading...

abivertinib; AC0010; EGFR; NSCLC; T790M; Phase 1